Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10176546 | 0.90 | HPGD (0.48) | HPGDHRH3KDM4EPOLBMAOA | |
| SCHEMBL651663 | 0.84 | MAPT (0.42) | HPGDHRH3POLBMAOAMAOB | |
| SCHEMBL651664 | 0.84 | MAPT (0.42) | HPGDHRH3POLBMAOAMAOB | |
| SCHEMBL651233 | 0.84 | HPGD (0.42) | HPGDRNASELDYRK3 | |
| SCHEMBL651235 | 0.84 | HPGD (0.42) | HPGDRNASELDYRK3 | |
| SCHEMBL651201 | 0.78 | HPGD (0.43) | HPGDHRH3KDM4EPOLB | |
| SCHEMBL651200 | 0.78 | HPGD (0.43) | HPGDHRH3KDM4EPOLB | |
| SCHEMBL10176429 | 0.77 | HPGD (0.42) | HPGDHRH3KDM4EPOLBMAOA | |
| SCHEMBL711443 | 0.77 | KDM4E (0.39) | HPGDHRH3KDM4EPOLB | |
| SCHEMBL10176434 | 0.76 | HPGD (0.41) | HPGDHRH3KDM4EPOLBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423204-A1 | THIAZOLIDINONE DERIVATIVE | SBI Biotech Co., Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | CDC7, CDK17, CDCA2 | HPGD 3970/4885HRH3 4616/4885KDM4E 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.